Enjoy complimentary customisation on priority with our Enterprise License!
The castration-resistant prostate cancer (CRPC) treatment market size is forecast to increase by USD 5.98 billion at a CAGR of 8.83% between 2023 and 2028. Prostate cancer is a significant health concern in the US, with castration-resistant prostate cancer (CRPC) being a challenging stage that requires innovative treatment approaches. The CRPC treatment landscape is evolving, with various options such as chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy. Clinical trials are ongoing to evaluate the efficacy and side effects of these treatments. Chemotherapy, including docetaxel and cabazitaxel, remains a standard treatment option, but it comes with side effects like neutropenia and peripheral neuropathy. Immunotherapy, like sipuleucel-T and PROSTVAC, harnesses the power of the immune system to fight cancer cells. Radiopharmaceutical therapy, such as radium-223 dichloride, targets bone metastases, reducing skeletal-related events. Targeted therapies, like abiraterone acetate and enzalutamide, inhibit androgen production. While these treatments offer hope, they also come with potential health complications, necessitating careful consideration and ongoing research for improved treatment options and reduced side effects.
_treatment_market_size_abstract_2024_v1.jpg.webp?v4.1.20)
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.